Magaldrate
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a682683 |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Negligible |
| Metabolism | Nil |
| Excretion | Fecal and renal |
| Identifiers | |
| |
ECHA InfoCard | 100.115.465 |
| Chemical and physical data | |
| Formula | AlMg2(OH)7·H2O |
| Molar mass | 212.66 g/mol |
| |
| (verify) | |
![{\displaystyle {\ce {[Al^{3+}][Mg^{2+}]2[HO^{-}]7[H2O]}}}](https://wikimedia.org/api/rest_v1/media/math/render/svg/49fcdf433bf4845c661d73d01328ab3f7a591223)
Magaldrate (
gastroesophageal reflux
.
Development
Magaldrat was first synthesized by the German chemist Gunther Hallmann and patented on February 2, 1960, by Byk Gulden Lomberg Chemische Fabrik (Germany).[1] In 1983, the active substance was registered as the original drug Riopan.[2]
Available forms
Magaldrate is available in the form of oral suspension or tablets.
Pharmacology
Magaldrate is a hydroxymagnesium aluminate complex that is converted rapidly by gastric acid into Mg(OH)2 and Al(OH)3, which are absorbed poorly and thus provide a sustained antacid effect.[3]
Interactions and adverse reactions
Magaldrate may negatively influence drugs like
indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea
.
References
 | This article needs additional citations for verification. (September 2014) |
- ^ US patent 2923660, Hallmann G, "Process for the preparation of magnesium aluminate hydrate, and therapeutic agents so produced", issued 1960-02-02, assigned to Byk Gulden Lomberg Chem. Fab.
- ^ Fachinfo Riopan Magen Tabletten, Stand Dezember 2014.
- ^ Laurence BL. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed.